Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Combined with Corticosteroids for Acquired Hemophilia A
NCT05849740Phase 4Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2023
- Primary completion
- Apr 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daratumumab in acquired hemophilia A (AHA), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Total response rate to treatment (OR) at 8 weeks. Started May 2023; status: recruiting.
02
Drugs
daratumumab
03
Conditions
acquired hemophilia A (AHA)
Beyond the preview
Go deeper on NCT05849740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849740.